A Double-blind, Randomised Study to Assess the Influence of Tiotropium (Spiriva®)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00257452|
Recruitment Status : Completed
First Posted : November 23, 2005
Last Update Posted : November 1, 2013
|Condition or disease||Intervention/treatment||Phase|
|Healthy||Drug: tiotropium 18 mcg or 54 mcg qd Drug: placebo matching tiotropium qd Drug: moxifloxacin 200 mg||Phase 1|
The objective of this study is to demonstrate that tiotropium does not prolong the QT interval more than placebo. This will be achieved by testing non-inferiority hypothesis.
There is one primary variable to be tested for non-inferiority: tiotropium high dose compared to placebo:
H0: µ(TIO,12) - µ(PBO,12) >= 10 ms vs. H1: µ(TIO,12) - µ(PBO,12) < 10 ms where µ(TIO,12), µ(PBO,12) represent the mean change from baseline QTcF between 5 minutes and 2 hours after 12 days of treatment (taking the mean of the time-matched differences between baseline and post-baseline values in each treatment period) with tiotropium 54 µg, or placebo, respectively.
If the data suggest that the Fridericia correction is poor for the study population, an alternative correction will be explored (QTcN). The other correction formula would be used as a replacement for the Fridericia correction and would be defined before unblinding of the data.
Placebo, moxifloxacin as active control
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||56 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||A Double-blind, Randomised, Placebo Controlled, Three-way Cross-over Study With an Open Label Positive Control (Moxifloxacin) to Assess the Influence of Inhaled Tiotropium Once Daily Over Twelve Days on the QTC Interval of the ECG in Healthy Male and Female Volunteers|
|Study Start Date :||October 2004|
|Actual Primary Completion Date :||July 2005|
|Study Completion Date :||July 2005|
- Mean change from baseline of the corresponding QTcF values of all ECGs taken from 5 minutes to 2 hours after dosing [ Time Frame: Day 12 ]
- Mean change from baseline of the corresponding QTcF values of all ECGs taken from 5 minutes to 2 hours after dosing [ Time Frame: Day 1 ]
- Mean change from baseline of the corresponding QTcF values of all ECGs taken from 5 minutes to 24 hours after dosing [ Time Frame: Day 1 and 12 ]
- Difference (tiotropium minus placebo) between the maximal time-matched change from baseline of the QTcF values of all ECGs taken from 0:05 - 23:50 after dosing [ Time Frame: Day 1 and 12 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00257452
|Ingelheim/Rhein, Germany, 55216|
|Study Chair:||Boehringer Ingelheim Study Coordinator||B.I. Pharma GmbH & Co. KG|